Table 1 The characteristics of the 78 patients who underwent whole-brain radiation therapy
Age, yrs.; mean (SD): | |
|---|---|
Total | 61.8 (11.5) |
< 65 | 45 (58) |
≥ 65 | 33 (42) |
Gender: | |
Male | 43 (55) |
Female | 35 (45) |
Primary cancer: | |
Lung, non-small-cell | 36 (46) |
Breast | 12 (15) |
Lung, small-cell | 6 (8) |
Others | 24 (31) |
KPS: | |
100–90 | 26 (33) |
80 | 24 (31) |
70 | 16 (21) |
60 | 12 (15) |
No. of brain metastases: | |
Solitary | 17 (22) |
Oligo (2–4) | 16 (21) |
Multiple (5 = <) | 34 (43) |
Meningeal carcinomatosis | 11 (14) |
GPA: | |
4.0–3.0 | 5 (6) |
2.5–2.0 | 20 (26) |
1.5–1.0 | 32 (51) |
0.5–0.0 | 21 (27) |
WBRT schedule: | |
35 Gy/14 fr | 63 (81) |
30 Gy/10 fr | 7 (9) |
Others | 5 (6) |
Uncompleted | 3 (4) |
Treatment: | |
WBRT only | 47 (60) |
WBRT + SRS | 11 (14) |
WBRT + Surgery (+/−SRS) | 20 (26) |
Systemic therapies prior to WBRT | |
No | 23 (29) |
Yes | 55 (71) |
Cytotoxic chemotherapy | 50 (64) |
Molecular targeted therapy | 25 (32) |
Hormonal therapy | 7 (9) |
Immunotherapy | 2 (3) |
No. of examinations: | |
1: BL only | 37 (48) |
2: BL and 4 mos. | 12 (15) |
3: BL, 4 mos. and 8 mos. | 29 (37) |
Examination compliance:%, (/): | |
At 4 mos. | 85% (41/48) |
At 8 mos. | 81% (29/36) |